D. Right, You description of Type I and Type II is good, but comments on drug conbinations are out in left field.
Pramlintide is an analog of Amylin, a natural hormone. However, LGND's Panretin IS a hormone (9-cis retinoic acid), the first non-polypeptide discovered in over 25 years!
Panretin could be a hormone treatment for type II diabetes because it activates RXRs (the NATURAL partner of PPARs, additional NATURAL HORMONE receptors). RXRs and PPARs are hormone receptors. LGND has started diabetes trials with Targretin, because it is more specific for RXRs (Panretin, the natural hormone, activates RXRs and RARs - Targretin, a rexinoid, only reacts with RXRs).
Last week, LGND HALTED their topical Panretin trial for KS. Today, they announced induction of complete remissions for another cancer, APL, using the oral form of Panretin.
Just as Pramlintide is an analog of a natural hormone, Panretin IS a natural hormone, and Targretin, a rexinoid, is an analog. Moreover, combining Rezulin, an analog for the hormone that activates PPARs, with Targretin, an analog for the hormone that activates RXRs, produces a NATURAL synergy. The two activated receptors, NATURALLY partner to overcome insulin resistance, the underlying cause of type II diabetes. Combining the two drugs INCREASES SPECIFICITY for overcoming insulin resistance (activated RXRs actually partner with several other hormone receptors also - by using Rezulin or a second generation TZD, the specificity for type II diabetes is INCREASED, leading to SAFER drugs (because they can be used at lower concentrations). |
